Abdelfettah Souhila, Boulay Gaylor, Dubuissez Marion, Spruyt Nathalie, Garcia Sara P, Rengarajan Shruthi, Loison Ingrid, Leroy Xavier, Rivera Miguel N, Leprince Dominique
University de Lille, CNRS, Institut Pasteur de Lille, UMR 8161m M3T, Mechanisms of Tumorigenesis and Targeted Therapies, F-59000 Lille, France.
Department of Pathology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Oncotarget. 2020 Mar 24;11(12):1051-1074. doi: 10.18632/oncotarget.27511.
Polycomb repressive complex 2 (PRC2) allows the deposition of H3K27me3. PRC2 facultative subunits modulate its activity and recruitment such as hPCL3/PHF19, a human ortholog of Drosophila Polycomb-like protein (PCL). These proteins contain a TUDOR domain binding H3K36me3, two PHD domains and a "Winged-helix" domain involved in GC-rich DNA binding. The human PCL3 locus encodes the full-length hPCL3L protein and a shorter isoform, hPCL3S containing the TUDOR and PHD1 domains only. In this study, we demonstrated by RT-qPCR analyses of 25 prostate tumors that hPCL3S is frequently up-regulated. In addition, hPCL3S is overexpressed in the androgen-independent DU145 and PC3 cells, but not in the androgen-dependent LNCaP cells. knockdown decreased the proliferation and migration of DU145 and PC3 whereas its forced expression into LNCaP increased these properties. A mutant hPCL3S unable to bind H3K36me3 (TUDOR-W50A) increased proliferation and migration of LNCaP similarly to wt hPCL3S whereas inactivation of its PHD1 domain decreased proliferation. These effects partially relied on the up-regulation of genes known to be important for the proliferation and/or migration of prostate cancer cells such as , and . Collectively, our results suggest hPCL3S as a new potential therapeutic target in castration resistant prostate cancers.
多梳抑制复合物2(PRC2)可实现H3K27me3的沉积。PRC2的兼性亚基可调节其活性和募集,例如hPCL3/PHF19,它是果蝇多梳样蛋白(PCL)的人类同源物。这些蛋白质包含一个结合H3K36me3的TUDOR结构域、两个PHD结构域以及一个参与富含GC的DNA结合的“翼状螺旋”结构域。人类PCL3基因座编码全长hPCL3L蛋白和一种较短的异构体hPCL3S,后者仅包含TUDOR和PHD1结构域。在本研究中,我们通过对25例前列腺肿瘤进行RT-qPCR分析证明,hPCL3S经常上调。此外,hPCL3S在雄激素非依赖性DU145和PC3细胞中过表达,但在雄激素依赖性LNCaP细胞中未过表达。敲低可降低DU145和PC3的增殖和迁移,而将其强制表达至LNCaP细胞中则会增强这些特性。一种无法结合H3K36me3的突变型hPCL3S(TUDOR-W50A)与野生型hPCL3S类似地增加了LNCaP细胞的增殖和迁移,而其PHD1结构域的失活则降低了增殖。这些效应部分依赖于对已知对前列腺癌细胞增殖和/或迁移重要的基因的上调,例如 、 和 。总体而言,我们的结果表明hPCL3S是去势抵抗性前列腺癌的一个新的潜在治疗靶点。